Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes
E Jennifer Weil, Gudeta Fufaa, Lois I Jones, Tracy Lovato, Kevin V Lemley, Robert L Hanson, William C Knowler, Peter H Bennett, Berne Yee, Bryan D Myers, Robert G Nelson, E Jennifer Weil, Gudeta Fufaa, Lois I Jones, Tracy Lovato, Kevin V Lemley, Robert L Hanson, William C Knowler, Peter H Bennett, Berne Yee, Bryan D Myers, Robert G Nelson
Abstract
Angiotensin receptor blockers are renoprotective in hypertensive azotemic patients with type 2 diabetes, but their efficacy in early diabetic kidney disease is uncertain. We performed a 6-year randomized clinical trial in 169 American Indians with type 2 diabetes and normoalbuminuria (albumin/creatinine ratio [ACR] <30 mg/g; n = 91) or microalbuminuria (ACR 30-299 mg/g; n = 78) at baseline. The primary outcome was decline in glomerular filtration rate (GFR) to ≤60 mL/min or to half the baseline value in subjects who entered with GFR <120 mL/min. Another outcome was differences in glomerular structure at end of treatment. Subjects received 100 mg losartan or placebo daily. GFR was measured annually; 111 subjects underwent kidney biopsies. Only nine subjects reached the GFR outcome, and the unadjusted hazard ratio (losartan vs. placebo) was 0.50 (95% CI, 0.12-1.99). Differences in mesangial fractional volume were not estimated in the combined albuminuria groups because of an interaction with treatment assignment. In separate analyses, mesangial fractional volume was lower in subjects treated with losartan in the microalbuminuria group (18.8 vs. 25.6%; P = 0.02), but not in the normoalbuminuria group (19.6 vs. 17.8%; P = 0.86). Treatment with losartan may preserve some features of kidney structure in American Indians with type 2 diabetes and microalbuminuria.
Figures
References
- Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL Study Investigators . Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869
- Lewis EJ, Hunsicker LG, Clarke WR, et al. Collaborative Study Group . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–860
- Levey AS, Cattran D, Friedman A, et al. . Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009;54:205–226
- Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group . The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870–878
- Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383–393
- Mauer M, Zinman B, Gardiner R, et al. . Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361:40–51
- American Diabetes Association . Standards of medical care for patients with diabetes mellitus. Diabetes Care 2000;23(Suppl. 1):S32–S42
- Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, The Heart Outcomes Prevention Evaluation Study Investigators . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145–153
- Vasquez B, Flock EV, Savage PJ, et al. . Sustained reduction of proteinuria in type 2 (non-insulin-dependent) diabetes following diet-induced reduction of hyperglycaemia. Diabetologia 1984;26:127–133
- Chasson AL, Grady HJ, Stanley MA. Determination of creatinine by means of automatic chemical analysis. Tech Bull Regist Med Technol 1960;30:207–212
- Myers BD, Nelson RG, Tan M, et al. . Progression of overt nephropathy in non-insulin-dependent diabetes. Kidney Int 1995;47:1781–1789
- Weil EJ, Lemley KV, Mason CC, et al. . Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. Kidney Int 2012;82:1010–1017
- Weibel ER. Practical Methods for Biological Morphometry. New York, Academic Press, 1979
- Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984;74:1143–1155
- Fioretto P, Steffes MW, Mauer M. Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes 1994;43:1358–1364
- Pagtalunan ME, Miller PL, Jumping-Eagle S, et al. . Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997;99:342–348
- Bilous R, Chaturvedi N, Sjølie AK, et al. . Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009;151:11–20, W3-4
- The EUCLID Study Group . Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787–1792
- Pavkov ME, Knowler WC, Lemley KV, Mason CC, Myers BD, Nelson RG. Early renal function decline in type 2 diabetes. Clin J Am Soc Nephrol 2012;7:78–84
- Rudberg S, Osterby R, Bangstad HJ, Dahlquist G, Persson B. Effect of angiotensin converting enzyme inhibitor or beta blocker on glomerular structural changes in young microalbuminuric patients with type I (insulin-dependent) diabetes mellitus. Diabetologia 1999;42:589–595
- Ahmad J, Shafique S, Abidi SM, Parwez I. Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects. Diabetes Res Clin Pract 2003;60:131–138
- White KE, Pinel N, Cordonnier DJ, Bilous RW, Diabiopsies Group . Does ACE inhibition slow progression of glomerulopathy in patients with type 2 diabetes mellitus? Diabet Med 2001;18:933–936
- Lemley KV, Abdullah I, Myers BD, et al. . Evolution of incipient nephropathy in type 2 diabetes mellitus. Kidney Int 2000;58:1228–1237
- Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047–1053
- Pavkov ME, Bennett PH, Knowler WC, Krakoff J, Sievers ML, Nelson RG. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA 2006;296:421–426
- National Kidney Foundation . KDOQI Clinical Practice Guidelines for Diabetes and CKD: 2012 Update. Am J Kidney Dis 2012;60:850–886
Source: PubMed